⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3277640 | 1.00 | — | — | |
| SCHEMBL838240 | 1.00 | — | — | |
| SCHEMBL1653664 | 0.73 | — | — | |
| SCHEMBL1653665 | 0.73 | — | — | |
| SCHEMBL8966546 | 0.72 | TSHR (0.33) | — | |
| SCHEMBL8966543 | 0.72 | TSHR (0.33) | — | |
| SCHEMBL17078171 | 0.69 | — | — | |
| SCHEMBL17078172 | 0.69 | — | — | |
| SCHEMBL11993618 | 0.69 | — | — | |
| SCHEMBL4384161 | 0.67 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114591223-B | Beta-lactamase inhibitor compounds | 恩塔西斯治疗有限公司 | 2025-01-24 | — | — | CN | disclosed |
| EP-3512851-B1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | ENTASIS THERAPEUTICS LTD (GB) | 2022-07-06 | — | — | EP | disclosed |
| EP-3512851-B1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | ENTASIS THERAPEUTICS LTD (GB) | 2022-07-06 | — | — | EP | disclosed |
| CN-114591223-A | Beta-lactamase inhibitor compounds | 恩塔西斯治疗有限公司 | 2022-06-07 | — | — | CN | disclosed |
| CN-109715630-B | Beta-lactamase inhibitor compounds | 恩塔西斯治疗有限公司 | 2022-02-22 | — | — | CN | disclosed |
| US-10800778-B2 | Beta-lactamase inhibitor compounds | ENTASIS THERAPEUTICS LIMITED (GB) | 2020-10-13 | — | — | US | disclosed |
| US-10800778-B2 | Beta-lactamase inhibitor compounds | ENTASIS THERAPEUTICS LIMITED (GB) | 2020-10-13 | — | — | US | disclosed |
| EP-3512851-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | Entasis Therapeutics Limited (GB) | 2019-07-24 | — | — | EP | disclosed |
| US-20190202832-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | ENTASIS THERAPEUTICS LIMITED (GB) | 2019-07-04 | — | — | US | disclosed |
| US-20190202832-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | ENTASIS THERAPEUTICS LIMITED (GB) | 2019-07-04 | — | — | US | disclosed |
| WO-2018053215-A1 | BETA-LACTAMASE INHIBITOR COMPOUNDS | ENTASIS THERAPEUTICS LIMITED (GB) | 2018-03-22 | — | — | WO | disclosed |
| US-8350047-B2 | Methods of preparing secondary carbinamine compounds with boronic acids | THADANI AVINASH N (CA) | 2013-01-08 | — | — | US | disclosed |
| US-8350047-B2 | Methods of preparing secondary carbinamine compounds with boronic acids | THADANI AVINASH N (CA) | 2013-01-08 | — | — | US | disclosed |
| US-8143451-B2 | Reacting a ketone with an allyl boron compound anc ammonia or ammonium salt; synthons | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2012-03-27 | — | — | US | disclosed |
| US-8143451-B2 | Reacting a ketone with an allyl boron compound anc ammonia or ammonium salt; synthons | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2012-03-27 | — | — | US | disclosed |
| US-20100298572-A1 | METHODS OF PREPARING SECONDARY CARBINAMINE COMPOUNDS WITH BORONIC ACIDS | PANASONIC CORPORATION (JP) | 2010-11-25 | — | — | US | disclosed |
| US-20100298572-A1 | METHODS OF PREPARING SECONDARY CARBINAMINE COMPOUNDS WITH BORONIC ACIDS | PANASONIC CORPORATION (JP) | 2010-11-25 | — | — | US | disclosed |
| WO-2008119161-A1 | METHODS OF PREPARING SECONDARY CARBINAMINE COMPOUNDS WITH BORONIC ACIDS | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2008-10-09 | — | — | WO | disclosed |
| US-20080139847-A1 | METHODS OF PREPARING TERTIARY CARBINAMINE COMPOUNDS | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2008-06-12 | — | — | US | disclosed |
| US-20080139847-A1 | METHODS OF PREPARING TERTIARY CARBINAMINE COMPOUNDS | KANATA CHEMICAL TECHNOLOGIES INC. (CA) | 2008-06-12 | — | — | US | disclosed |